(Q38491964)

3 September 2017

Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer (English)

1 reference

3 September 2017

1 reference

ChEBI release 2020-05-28

1 reference

Peter D Boasberg

1

1 reference

3 September 2017

Charles H Redfern

2

1 reference

3 September 2017

Gregory A Daniels

3

1 reference

3 September 2017

David Bodkin

4

1 reference

3 September 2017

Chris R Garrett

5

1 reference

3 September 2017

Alejandro D Ricart

6

1 reference

3 September 2017

24 April 2011

1 reference

Cancer Chemotherapy and Pharmacology

3 September 2017

1 reference

3 September 2017

68

1 reference

3 September 2017

547-552

1 reference

3 September 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-011-1620-1

3 September 2017

0 references

cites work

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1620-1

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1620-1

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1620-1

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1620-1

Integrating signals from RTKs to ERK/MAPK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1620-1

Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1620-1

Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1620-1

Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1620-1

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1620-1

The role of Raf kinase inhibitor protein (RKIP) in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1620-1

Signalling molecules essential for neuronal survival and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1620-1

Activated MAPK/ERK kinase (MEK-1) induces transdifferentiation of pigmented epithelium into neural retina

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1620-1

Acetylcholine stimulates cortical precursor cell proliferation in vitro via muscarinic receptor activation and MAP kinase phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1620-1

Exercise, MAPK, and NF-kappaB signaling in skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1620-1

Mitogen-activated protein kinases: a new therapeutic target in cardiac pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1620-1

10.1007/S00280-011-1620-1

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

3 September 2017

0 references

1 reference